Alaunos Therapeutics, Inc. Operating Income Loss

• Alaunos Therapeutics, Inc. showed an increase of +12.2% in Operating Income Loss from 2024 to 2025.
• This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Alaunos Therapeutics, Inc.'s Operating Income Loss has grown by 65.1%.
• Historical annual values: Fiscal year 2025: -$4.23 million | Fiscal year 2024: -$4.81 million | Fiscal year 2023: -$34.27 million | Fiscal year 2022: -$35.11 million | Fiscal year 2021: -$77.55 million | Fiscal year 2020: -$80.36 million | Fiscal year 2019: -$57.86 million | Fiscal year 2018: -$53.91 million | Fiscal year 2017: -$53.49 million | Fiscal year 2016: -$165.31 million | Fiscal year 2015: -$120.10 million | Fiscal year 2014: -$43.50 million | Fiscal year 2013: -$57.71 million | Fiscal year 2012: -$102.17 million | Fiscal year 2011: -$71.40 million | Fiscal year 2010: -$24.55 million | Fiscal year 2009: -$12.12 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026